CSTL
Castle Biosciences Inc
NASDAQ: CSTL · HEALTHCARE · DIAGNOSTICS & RESEARCH
$24.49
+1.03% today
Updated 2026-04-30
Market cap
$734.37M
P/E ratio
—
P/S ratio
2.13x
EPS (TTM)
$-0.83
Dividend yield
—
52W range
$15 – $44
Volume
0.4M
Castle Biosciences Inc (CSTL) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-7.02%
Operating margin
-4.40%
ROE
-5.21%
ROA
-2.56%
Debt/equity
0.08x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2017 | $13.75M | $-12.37M | 64.21% | -79.25% | -89.93% |
| 2018 | $22.79M | $-6.37M | 76.75% | -16.83% | -27.94% |
| 2019 | $51.87M | $5.28M | 85.91% | 14.13% | 10.17% |
| 2020 | $62.65M | $-10.28M | 84.54% | -10.44% | -16.42% |
| 2021 | $94.08M | $-31.29M | 83.18% | -42.60% | -33.26% |
| 2022 | $137.04M | $-67.14M | 76.64% | -53.16% | -48.99% |
| 2023 | $219.79M | $-57.47M | 79.53% | -30.93% | -26.15% |
| 2024 | $332.07M | $18.25M | 81.87% | 2.61% | 5.49% |
| 2025 | $344.23M | $-24.16M | 68.66% | -12.44% | -7.02% |